1

Inpharma 1667 - 6 Dec 2008 ■ US FDA grants orphan drug status to pralatrexate. The agent is being developed by Allos Therapeutics and is indicated for the treatment of patients with diffuse large B-cell lymphoma. Allos Therapeutics Inc. U.S. FDA Grants Pralatrexate Orphan Drug Designation for the Treatment of Patients with Diffuse Large B-Cell Lymphoma. Media Release : 25 Nov 2008. Available from: URL: http:// www.allos.com 809095780 1 Inpharma 6 Dec 2008 No. 1667 1173-8324/10/1667-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved

US FDA grants orphan drug status to pralatrexate

Download PDF Report

View
213
Download
1

Embed Size (px)

Citation preview

Page 1: US FDA grants orphan drug status to pralatrexate

Inpharma 1667 - 6 Dec 2008

■ US FDA grants orphan drug status to pralatrexate.The agent is being developed by Allos Therapeuticsand is indicated for the treatment of patients withdiffuse large B-cell lymphoma.Allos Therapeutics Inc. U.S. FDA Grants Pralatrexate Orphan DrugDesignation for the Treatment of Patients with Diffuse Large B-CellLymphoma. Media Release : 25 Nov 2008. Available from: URL: http://www.allos.com 809095780

1

Inpharma 6 Dec 2008 No. 16671173-8324/10/1667-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved

Documents

$On the Horizon: Emerging Systemic Therapies for T-Cell ... Pro.pdf · Relapsed/Refractory PTCL FDA-Approved agents Agent Dose/schedule N ORR (%) CR (%) DOR, Mos Pralatrexate 30 mg/m2$

On the Horizon: Emerging Systemic Therapies for T-Cell ... Pro.pdf · Relapsed/Refractory PTCL FDA-Approved agents Agent Dose/schedule N ORR (%) CR (%) DOR, Mos Pralatrexate 30 mg/m2

Documents

Introducing Orphan Tools The Orphan Index & Lifespan Manager

Introducing Orphan Tools The Orphan Index & Lifespan Manager

Documents

Development of Orphan Drugs – Regulatory Viewpoints from ...Orphan drugs • “In all, more than one-third of new drugs approved by the FDA last year were orphans.” • “In

Development of Orphan Drugs – Regulatory Viewpoints from ...Orphan drugs • “In all, more than one-third of new drugs approved by the FDA last year were orphans.” • “In

Documents

FDA orphan designation - European Medicines Agency cell disease ... – Must provide a specific number; not enough to say that the disease occurs in

FDA orphan designation - European Medicines Agency cell disease ... – Must provide a specific number; not enough to say that the disease occurs in

Documents

Documents

Orphan designation withdrawal assessment report - Vitrakvi · Orphan designation withdrawal assessment report . Vitrakvi (larotrectinib) Sponsor: Bayer AG ... Orphan designation withdrawal

Orphan designation withdrawal assessment report - Vitrakvi · Orphan designation withdrawal assessment report . Vitrakvi (larotrectinib) Sponsor: Bayer AG ... Orphan designation withdrawal

Documents

Australian public assessment for Pralatrexate · Web viewPDX-3501 (Protocol synopsis submitted) – a randomised, comparative, open-label, study of pralatrexate vs. treatment of

Australian public assessment for Pralatrexate · Web viewPDX-3501 (Protocol synopsis submitted) – a randomised, comparative, open-label, study of pralatrexate vs. treatment of

Documents

ORPHAN - ihh.org.tr

ORPHAN - ihh.org.tr

Documents

Presentations - Orphan designation - Key concepts and ... · Orphan designation Key concepts and ... 6.0% 3.0% Marketing authorisations Protocol assistance ... Orphan designation

Presentations - Orphan designation - Key concepts and ... · Orphan designation Key concepts and ... 6.0% 3.0% Marketing authorisations Protocol assistance ... Orphan designation

Documents

Orphan Medicines - 2020health · 2020-06-21 · for orphan drug and non-orphan drug innovative medicines Table 11: Recommendations for agencies 46 for selected orphan drugs in eleven

Orphan Medicines - 2020health · 2020-06-21 · for orphan drug and non-orphan drug innovative medicines Table 11: Recommendations for agencies 46 for selected orphan drugs in eleven

Documents

An agency of the European Union EU publicly funded research programs FDA/EMA Orphan Designation and Grant Workshop (12 Oct 2012) Presented by: Jordi Llinares

An agency of the European Union EU publicly funded research programs FDA/EMA Orphan Designation and Grant Workshop (12 Oct 2012) Presented by: Jordi Llinares

Documents

Katherine Needleman, MS, PhD, RAC Director, Orphan Products Grants Program FDA/OOPD FDA/EMA Orphan Designation & Grant Workshop October 12, 2012 Orphan

Katherine Needleman, MS, PhD, RAC Director, Orphan Products Grants Program FDA/OOPD FDA/EMA Orphan Designation & Grant Workshop October 12, 2012 Orphan

Documents

Background Paper 6.19 Rare Diseases - WHO · Clinical trial-funding programmes (e.g. FDA Orphan Products Grant Program, EU Seventh Framework Programme (FP7)) remain essential for

Background Paper 6.19 Rare Diseases - WHO · Clinical trial-funding programmes (e.g. FDA Orphan Products Grant Program, EU Seventh Framework Programme (FP7)) remain essential for

Documents

NORD Study of FDA Approval of Orphan Drugs

NORD Study of FDA Approval of Orphan Drugs

Documents

FDA Marks Orphan Drug Act Milestone: 30 Year Recognition January 2013

FDA Marks Orphan Drug Act Milestone: 30 Year Recognition January 2013

Documents

About the Orphan Trains The Orphan Trains started in 1854 through 1929. The Orphan Trains took children to the West in hope for a better life. The Orphan

About the Orphan Trains The Orphan Trains started in 1854 through 1929. The Orphan Trains took children to the West in hope for a better life. The Orphan

Documents

Orphan powerpoint

Orphan powerpoint

Documents

FDA orphan designation · #2 – Is the Disease Rare? (cont.) • If disease/condition is common (i.e., occurs in > 200K persons in the US), can grant orphan designation for use in

FDA orphan designation · #2 – Is the Disease Rare? (cont.) • If disease/condition is common (i.e., occurs in > 200K persons in the US), can grant orphan designation for use in

Documents

Research Pralatrexate Is Synergistic with the Proteasome Inhibitor ... · Pralatrexate Is Synergistic with the Proteasome Inhibitor Bortezomib in In vitro and In vivo Models of T-Cell

Research Pralatrexate Is Synergistic with the Proteasome Inhibitor ... · Pralatrexate Is Synergistic with the Proteasome Inhibitor Bortezomib in In vitro and In vivo Models of T-Cell

Documents

ANNUAL REPORT 2018 · Orphan Drug designation is a special status that the FDA may grant to a drug to treat a rare disease or condition. Amongst other incentives, Orphan Drug designation

ANNUAL REPORT 2018 · Orphan Drug designation is a special status that the FDA may grant to a drug to treat a rare disease or condition. Amongst other incentives, Orphan Drug designation

Documents

Innovating in Orphan Diseases in Orphan...Orphan drugs policies have been successful as they incentivise the development of new therapies 7 The FDA has approved more than 640 ORPHAN

Innovating in Orphan Diseases in Orphan...Orphan drugs policies have been successful as they incentivise the development of new therapies 7 The FDA has approved more than 640 ORPHAN

Documents

Education

Corporate Presentation - GenSight Biologics€¦ · GENSIGHT-BIOLOGICS.COM Corporate Presentation November 2019. Disclaimer This document contains forward-looking ... (FDA & EMA Orphan

Corporate Presentation - GenSight Biologics€¦ · GENSIGHT-BIOLOGICS.COM Corporate Presentation November 2019. Disclaimer This document contains forward-looking ... (FDA & EMA Orphan

Documents

November 2018 ORPHAN DRUGS · orphan drug processes. In this report, GAO examines, among other things, (1) the actions FDA has taken to address the growing demand for orphan designations;

November 2018 ORPHAN DRUGS · orphan drug processes. In this report, GAO examines, among other things, (1) the actions FDA has taken to address the growing demand for orphan designations;

Documents

Restoring the Foundations Orphan Heart Orphan Lifestyle Chester and Betsy Kylstra

Restoring the Foundations Orphan Heart Orphan Lifestyle Chester and Betsy Kylstra

Documents

BPI-Informationsbroschüre Orphan Drugs · ORPHAN DRUGS Stand der Dinge: Die EU-weite Orphan-Drug-Gesetzgebung Stand der Dinge: Die EU-weite Orphan-Drug-Gesetzgebung Um den wirtschaftlichen

BPI-Informationsbroschüre Orphan Drugs · ORPHAN DRUGS Stand der Dinge: Die EU-weite Orphan-Drug-Gesetzgebung Stand der Dinge: Die EU-weite Orphan-Drug-Gesetzgebung Um den wirtschaftlichen

Documents

The Economic Power of Orphan Drugsdtr-pharma.com/wp-content/...POWER-of-Orphan-Drugs.pdf · control group of non-orphan drugs. This data, combined with the increasing number of orphan

The Economic Power of Orphan Drugsdtr-pharma.com/wp-content/...POWER-of-Orphan-Drugs.pdf · control group of non-orphan drugs. This data, combined with the increasing number of orphan

Documents

EvaluatePharma Orphan Drug Report 2015 · The Orphan Drug Report also reveals that worldwide orphan drug sales will reach $178bn by 2020. The proportion of orphan drugs in relation

EvaluatePharma Orphan Drug Report 2015 · The Orphan Drug Report also reveals that worldwide orphan drug sales will reach $178bn by 2020. The proportion of orphan drugs in relation

Documents

Improving Health Outcomes in HIV Immunologic Non ... FDA Conf Call Minutes Final.pdfImproving Health Outcomes in HIV Immunologic Non-Responders (INRs) Orphan Drug Designation Possibilities

Improving Health Outcomes in HIV Immunologic Non ... FDA Conf Call Minutes Final.pdfImproving Health Outcomes in HIV Immunologic Non-Responders (INRs) Orphan Drug Designation Possibilities

Documents